Randomized Double-blind Safety and Efficacy of Recombinant Human Erythropoietin in Amyotrophic Lateral Sclerosis

  • End date
    Dec 22, 2025
  • participants needed
  • sponsor
    Hanyang University Seoul Hospital
Updated on 22 January 2021


Erythropoietin is neuroprotective in animal models of neurodegenerative diseases including amyotrophic lateral sclerosis (ALS). The aim of this study was to determine the safety and feasibility of repetitive high-dose recombinant human erythropoietin (rhEPO) therapy in ALS patients.

Condition Myelopathy, Spinal Cord Disorders, Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis (ALS), Spinal Cord Disorders, lou gehrig's disease
Treatment recombinant human erythropoietin(rhEPO)
Clinical Study IdentifierNCT03835507
SponsorHanyang University Seoul Hospital
Last Modified on22 January 2021


Yes No Not Sure

Inclusion Criteria

Age between 25 to 80
upper motor neuron signs and lower motor neuron signs were identified in neurological examination
Meet the revised El Escorial Criteria for clinically possible, probable-laboratory -supported, probable, definite ALS
Disease duration < 3 years (Within 3 years from symptom onset)
ALSFRS-R score between 21 to 46
Patient who can visit an outpatient under the aid of his or her own walking or caregivers
The person who have agreed in writing to participate in this clinical trial by themselves and the legal representative
FVC over 50% at screening

Exclusion Criteria

Person who were not compatible with ALS
Patient with PLS or PMA
A group of patients who are concerned about the adverse effects of the drug administration (e.g. malignant hypertension,...)
ALSFRS-R score below 20 at screening
Ventilator user or Tracheostomy state patients at screening
Gastrostomy state at screening
FVC below 50% at screening or patient who cannot perform FVC test
EKG abnormality, history of coronary stent , CABG at screening
Person who was given another clinical trial drug three months prior to screening
History of seizure/ epilepsy
Abnormal renal function (serem creatinine > 2.0mg/dl)
Abnormal liver function(AST/ALT/bilirubin over 2 times the upper normal limit
Bleeding tendency at screening
Infectious disease at screening
Drug sensitivity
Person who injected erythropoietin 6 months prior to screening
Malignant tumor
Other neurological disease (stroke, parkinson's disease, dementia...)
Psychological disease
Hb more than 16g/dL
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note